Cantor Fitzgerald set a $10.00 price target on Amarin (NASDAQ:AMRN) in a research report report published on Tuesday, December 19th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AMRN has been the subject of several other reports. ValuEngine lowered shares of Amarin from a hold rating to a sell rating in a report on Thursday, November 16th. Zacks Investment Research lowered shares of Amarin from a hold rating to a sell rating in a report on Tuesday, December 12th. HC Wainwright reiterated a buy rating and set a $10.00 target price on shares of Amarin in a report on Thursday, November 2nd. Jefferies Group reiterated a buy rating on shares of Amarin in a report on Wednesday, October 11th. Finally, BidaskClub lowered shares of Amarin from a sell rating to a strong sell rating in a report on Thursday, August 24th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Amarin presently has an average rating of Buy and a consensus price target of $7.75.
Amarin (NASDAQ AMRN) traded down $0.05 during midday trading on Tuesday, hitting $4.25. The company had a trading volume of 844,368 shares, compared to its average volume of 1,636,314. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48. Amarin has a 12 month low of $2.81 and a 12 month high of $4.47. The company has a market capitalization of $1,164.78, a PE ratio of -15.74 and a beta of 0.62.
Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $45.85 million. During the same quarter last year, the business earned ($0.08) earnings per share. The business’s quarterly revenue was up 45.4% on a year-over-year basis. equities analysts anticipate that Amarin will post -0.22 EPS for the current year.
In other Amarin news, insider Steven B. Ketchum sold 64,683 shares of Amarin stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $4.40, for a total value of $284,605.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Steven B. Ketchum sold 128,257 shares of Amarin stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $4.25, for a total transaction of $545,092.25. The disclosure for this sale can be found here. Insiders own 3.72% of the company’s stock.
Several hedge funds have recently modified their holdings of AMRN. Alkeon Capital Management LLC bought a new stake in shares of Amarin during the 3rd quarter valued at $7,875,000. University of Notre Dame DU Lac bought a new stake in shares of Amarin during the 3rd quarter valued at $2,814,000. JPMorgan Chase & Co. lifted its stake in shares of Amarin by 681.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock valued at $1,121,000 after buying an additional 242,544 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Amarin by 135.4% during the 2nd quarter. GSA Capital Partners LLP now owns 342,800 shares of the biopharmaceutical company’s stock valued at $1,381,000 after buying an additional 197,200 shares in the last quarter. Finally, Intrinsic Edge Capital Management LLC purchased a new position in shares of Amarin during the 2nd quarter valued at $725,000. 40.12% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/14/cantor-fitzgerald-analysts-give-amarin-amrn-a-10-00-price-target.html.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.